Valion Bio (VBIO) Shares Outstanding (2021 - 2026)
Valion Bio (VBIO) posted quarterly Shares Outstanding (Entity) of $1.2 million for Q4 2025, up 302.11% year-over-year from $287370.0 in Q4 2024, and down 12.51% quarter-over-quarter from $1.3 million in Q3 2025.
Valion Bio (VBIO) Shares Outstanding (2021 - 2026) Analysis & Trends
Valion Bio's Shares Outstanding (Entity) history runs 5 years deep, the most recent figure standing at $1.2 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) rose 302.11% year-over-year to $1.2 million; the TTM figure through Dec 2025 stood at $1.2 million (up 302.11% YoY), while the FY2025 annual figure was $1.2 million, up 302.11% from the prior year.
- Shares Outstanding (Entity) for Q4 2025 stood at $1.2 million, down from $1.3 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $29.7 million in Q2 2023, with the low at $287370.0 in Q4 2024.
- The 5-year median for Shares Outstanding (Entity) is $2.5 million (2021), against an average of $5.9 million.
- Peak annual rise in Shares Outstanding (Entity) reached 424.73% in 2024, while the deepest fall reached 92.68% in 2024.
- Valion Bio's Shares Outstanding (Entity) stood at $3.5 million in 2021, then surged by 177.04% to $9.7 million in 2022, then sank by 91.81% to $793043.0 in 2023, then tumbled by 63.76% to $287370.0 in 2024, then jumped by 302.11% to $1.2 million in 2025.
- Business Quant data shows VBIO's Shares Outstanding (Entity) at $1.2 million in Q4 2025, $1.3 million in Q3 2025, and $965899.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 133.61 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 217.35 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 445.06 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 241.70 Mn |
| 10 | Valion Bio | 420,133.64 | -1.78 Mn | -45,000.00 | 3.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.38 Mn |
| Dec 31, 2025 | 1.16 Mn |
| Sep 30, 2025 | 1.32 Mn |
| Jun 30, 2025 | 881,294.00 |
| Mar 31, 2025 | 596,368.00 |
| Dec 31, 2024 | 287,370.00 |
| Sep 30, 2024 | 6.19 Mn |
| Jun 30, 2024 | 4.01 Mn |
| Mar 31, 2024 | 1.47 Mn |
| Dec 31, 2023 | 793,043.00 |
| Sep 30, 2023 | 1.19 Mn |
| Jun 30, 2023 | 29.68 Mn |
| Mar 31, 2023 | 20.12 Mn |
| Dec 31, 2022 | 9.67 Mn |
| Sep 30, 2022 | 9.68 Mn |
| Jun 30, 2022 | 9.62 Mn |
| Mar 31, 2022 | 9.72 Mn |
| Dec 31, 2021 | 3.49 Mn |
| Sep 30, 2021 | 2.58 Mn |
| Jun 30, 2021 | 2.37 Mn |